These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 20393265

  • 1. The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen.
    Mercadante S, Villari P, Ferrera P, Mangione S, Casuccio A.
    Clin J Pain; 2010 May; 26(4):306-9. PubMed ID: 20393265
    [Abstract] [Full Text] [Related]

  • 2. Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study.
    Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, Mangione S.
    J Pain Symptom Manage; 2008 Mar; 35(3):307-13. PubMed ID: 18178368
    [Abstract] [Full Text] [Related]

  • 3. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain.
    Mercadante S, Villari P, Ferrera P, Casuccio A, Mangione S, Intravaia G.
    Br J Cancer; 2007 Jun 18; 96(12):1828-33. PubMed ID: 17519902
    [Abstract] [Full Text] [Related]

  • 4. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose.
    Mercadante S, Villari P, Ferrera P, Bianchi M, Casuccio A.
    J Pain Symptom Manage; 2004 Apr 18; 27(4):352-9. PubMed ID: 15050663
    [Abstract] [Full Text] [Related]

  • 5. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
    Mercadante S, Villari P, Ferrera P, Porzio G, Aielli F, Verna L, Casuccio A.
    J Pain Symptom Manage; 2006 Aug 18; 32(2):175-9. PubMed ID: 16877185
    [Abstract] [Full Text] [Related]

  • 6. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
    Mercadante S, Ferrera P, Adile C, Casuccio A.
    J Pain Symptom Manage; 2011 Sep 18; 42(3):464-9. PubMed ID: 21477977
    [Abstract] [Full Text] [Related]

  • 7. The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen.
    Mercadante S, Prestia G, Casuccio A.
    Curr Med Res Opin; 2013 Nov 18; 29(11):1527-32. PubMed ID: 23869428
    [Abstract] [Full Text] [Related]

  • 8. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.
    Pain Pract; 2008 Nov 18; 8(4):287-313. PubMed ID: 18503626
    [Abstract] [Full Text] [Related]

  • 9. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
    Mercadante S, Gatti A, Porzio G, Lo Presti C, Aielli F, Adile C, Casuccio A.
    Curr Med Res Opin; 2012 Jun 18; 28(6):963-8. PubMed ID: 22480130
    [Abstract] [Full Text] [Related]

  • 10. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM, Messina J, Xie F, Hale M.
    Clin Ther; 2007 Apr 18; 29(4):588-601. PubMed ID: 17617282
    [Abstract] [Full Text] [Related]

  • 11. Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: a case series.
    Landy SH.
    Headache; 2004 Sep 18; 44(8):762-6. PubMed ID: 15330821
    [Abstract] [Full Text] [Related]

  • 12. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Verna L, Villari P, Ficorella C, Gebbia V, Riina S, Casuccio A, Mangione S.
    Eur J Pain; 2008 Nov 18; 12(8):1040-6. PubMed ID: 18353696
    [Abstract] [Full Text] [Related]

  • 13. Opioid switch in palliative care, opioid choice by clinical need and opioid availability.
    Müller-Busch HC, Lindena G, Tietze K, Woskanjan S.
    Eur J Pain; 2005 Oct 18; 9(5):571-9. PubMed ID: 16139186
    [Abstract] [Full Text] [Related]

  • 14. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M, Tempero K, Kirby M, Thompson J.
    Clin Ther; 2006 May 18; 28(5):715-24. PubMed ID: 16861093
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
    Chang AK, Bijur PE, Baccelieri A, Gallagher EJ.
    Am J Geriatr Pharmacother; 2009 Feb 18; 7(1):1-10. PubMed ID: 19281935
    [Abstract] [Full Text] [Related]

  • 16. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.
    Mercadante S, Ferrera P, Villari P, Casuccio A, Intravaia G, Mangione S.
    J Pain Symptom Manage; 2009 Apr 18; 37(4):632-41. PubMed ID: 19345298
    [Abstract] [Full Text] [Related]

  • 17. The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.
    Mercadante S, Porzio G, Aielli F, Averna L, Ficorella C, Casuccio A.
    Support Care Cancer; 2013 Aug 18; 21(8):2335-9. PubMed ID: 23564072
    [Abstract] [Full Text] [Related]

  • 18. Optimization of opioid therapy for preventing incident pain associated with bone metastases.
    Mercadante S, Villari P, Ferrera P, Casuccio A.
    J Pain Symptom Manage; 2004 Nov 18; 28(5):505-10. PubMed ID: 15504626
    [Abstract] [Full Text] [Related]

  • 19. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
    Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA, Frigerio V, Ingham J, Loseth DB, Nordbrock E, Rhiner M.
    Pain; 1999 Feb 18; 79(2-3):303-12. PubMed ID: 10068176
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG, Orońska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T.
    Clin Ther; 2009 Jun 18; 31(6):1177-91. PubMed ID: 19695386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.